NuVasive (NSDQ:NUVA) said today it launched its Reline MAS midline system designed to treat adjacent segment transition syndrome.
The newly launched system features low-profile modular implants and system instrumentation designed for alignment and the potential reduction of adjacent segment transition syndrome, the San Diego-based company said.
“RMM posterior fixation represents the most advanced midline cortical pedicle screw system on the market. The introduction of modular, low-profile tulip heads was designed to address concerns with adjacent segment facet joint impingement. This system furthers NuVasive’s midline portfolio as best-in-class,” Dr. Nitin Khanna of the Indiana University School of Medicine said in a prepared statement.
NuVasive said that the system is designed to be used with the company’s access and interbody technologies to provide a minimally invasive approach to bilateral decompression under complete visualization. The system supports both cortical and standard trajectory techniques, the company said.
“Innovation is in our DNA and we are constantly looking for ways to take our existing solutions to the next level. RMM, a low-profile midline solution that stands out with its versatility, strength and reliability, exemplifies our commitment to innovation and provides relevant solutions to meet the diverse and evolving needs of our surgeons worldwide,” exec VP Matt Link said in a press release.
Last month, NuVasive said it launched its AttraX scaffold ceramic-collagen bone graft in the US, touting that the scaffold’s surface has been shown to increase bone formation for faster fusion than standard ceramic bone grafts.
